Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON31628
NL-OMON31628
Recruiting
Phase 4

The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. - CEPS

Sint Lucas Andreas Ziekenhuis0 sites114 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionshyperparathyroidismincreased activity of the parathyroids1003394910029149

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
hyperparathyroidism
Sponsor
Sint Lucas Andreas Ziekenhuis
Enrollment
114
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Sint Lucas Andreas Ziekenhuis

Eligibility Criteria

Inclusion Criteria

  • •\- Hemodialysis patient \> 18 years
  • •\- Secondary hyperparathyoidism

Exclusion Criteria

  • •\- Severe hypercalcemia (Ca2\+ \> 2,65 mmol/L)
  • •\- Severe hepatic dysfunction
  • •\- Overdosage of digoxin
  • •\- Hypersensitivity to vitamine D or an overdosage of vitamin D
  • •\- Parathyroidectomy
  • •\- \< 18 years
  • •\- Pregnancy
  • •\- Mental illness

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. - CEPSSecondary hyperparathyroidismMedDRA version: 9.1Level: LLTClassification code 10020708Term: Hyperparathyroidism secondary
EUCTR2007-006645-41-NLSint Lucas Andreas Hospital
Not yet recruiting
Not Applicable
Research to (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism
NL-OMON24070Het Sint Lucas Andreas ziekenhuis114
Not yet recruiting
Not Applicable
Research to cost-effectiveness of paricalcitol of the treatment of secundary hyperparathyroidism at hemodialysis patients
NL-OMON24822Sint Lucas Andreas ziekenhuis114
Active, not recruiting
Not Applicable
Efficacy and safety of paricalcitol in the reduction of secondary hyperparathyroidism after kidney transplantation.Secondary hyperparathyroidism after renal transplantationMedDRA version: 16.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]
EUCTR2013-001326-25-ESFundación SENEFRO
Terminated
Phase 4
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis SubjectsSecondary HyperparathyroidismDialysis
NCT00664430Abbott13